Pathologic complete response to combination therapy with enfortumab vedotin and pembrolizumab in a patient with metastatic ureteral cancer

Asian Journal of Urology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles